No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
MCRB240621C1000
- 0.15
- 0.000.00%
15min DelayClose May 31 13:57 ET
0.15High0.10Low
0.10Open0.15Pre Close57 Volume16.57K Open Interest1.00Strike Price780.00Turnover108.59%IV10.00%PremiumJun 21, 2024Expiry Date0.00Intrinsic Value100Multiplier19DDays to Expiry0.15Time Value100Contract SizeAmericanOptions Type0.5537Delta1.5927Gamma10.00Leverage Ratio-0.0027Theta0.0002Rho5.54Eff Leverage0.0009Vega
Intraday
- 5D
- 1D
News
Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares Fly 26% But Investors Aren't Buying For Growth
Seres Therapeutics, Inc. (NASDAQ:MCRB) shareholders are no doubt pleased to see that the share price has bounced 26% in the last month, although it is still struggling to make up recently lost ground.
CCORF Maintains Seres Therapeutics(MCRB.US) With Buy Rating, Maintains Target Price $15
CCORF analyst John Newman maintains $Seres Therapeutics(MCRB.US)$ with a buy rating, and maintains the target price at $15.According to TipRanks data, the analyst has a success rate of 38.5% and a tot
Analysts Conflicted on These Healthcare Names: Seres Therapeutics (MCRB) and Immunocore Holdings (IMCR)
Seres Therapeutics(MCRB.US) Officer Sells US$882.66 in Common Stock
$Seres Therapeutics(MCRB.US)$ Officer von Moltke Lisa sold 939 shares of common stock on May 15, 2024 at an average price of $0.94 for a total value of $882.66.Source: Announcement What is statement o
Seres Therapeutics(MCRB.US) Officer Sells US$2,288.9 in Common Stock
$Seres Therapeutics(MCRB.US)$ Officer Shaff Eric D. sold 2,435 shares of common stock on May 15, 2024 at an average price of $0.94 for a total value of $2,288.9.Source: Announcement What is statement
Seres Therapeutics(MCRB.US) Officer Sells US$660.82 in Common Stock
$Seres Therapeutics(MCRB.US)$ Officer Young Teresa L. sold 703 shares of common stock on May 15, 2024 at an average price of $0.94 for a total value of $660.82.Source: Announcement What is statement o
Comments
$Seres Therapeutics(MCRB.US$ Seres Therapeutics Inc - Ser-155 Phase 1B Placebo-Controlled Cohort 2 Clinical Readout Expected End of Q3 2024
1
$Seres Therapeutics(MCRB.US$
their product vowst being referred (theirs is the only fda approved pill type) in the latest released of netflix documentary. no surprise that this has attracted many investors the past couple of days. Perhaps 0.95 - 1 dollar is now the new support. Alot of telling signs pointing to upcoming BO.. people speculating will be by Nestle. If all go smooth, this will be my first investment that gets a BO. 15k shares in it at 0.9 avg. they also have another drug on fda fas...
their product vowst being referred (theirs is the only fda approved pill type) in the latest released of netflix documentary. no surprise that this has attracted many investors the past couple of days. Perhaps 0.95 - 1 dollar is now the new support. Alot of telling signs pointing to upcoming BO.. people speculating will be by Nestle. If all go smooth, this will be my first investment that gets a BO. 15k shares in it at 0.9 avg. they also have another drug on fda fas...
1
1
Read more